Cyclo

Quick links to important sections

Cyclo

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyclo

What is Cyclo? (Chlortetracycline)

Property Description
Active ingredient Chlortetracycline Hydrochloride
Form Cutaneous Spray, Ointment, Capsule, Tablet
Pharmacological class Tetracycline Antibiotic, Anti-Infective Agent
General purpose Controls the growth of susceptible bacteria
Origin Natural-occurring (Streptomyces aureofaciens)

Cyclo is a medicine whose active component is Chlortetracycline Hydrochloride, an established agent classified as a broad-spectrum anti-infective. Its fundamental purpose is to control and suppress the growth of various susceptible bacteria.

Type, Origin, and Action

The active ingredient, Chlortetracycline, is categorized pharmacologically as a tetracycline antibiotic and is a significant compound because it was the first member of the tetracycline class to be identified. It is a natural-occurring substance, having been originally isolated from the soil microorganism Streptomyces aureofaciens in the 1940s. Its classification as broad-spectrum is clinically recognized and signifies its ability to influence a wide variety of common bacterial pathogens, distinguishing it within the anti-infective group. The compound's anti-bacterial efficacy is rooted in its mechanism of action, which is primarily bacteriostatic, preventing the bacteria from multiplying by interfering with their protein synthesis. This mechanism shows that the medicine works by limiting the bacteria's ability to grow and spread throughout the body or on the skin.

Composition, Forms, and Therapeutic Goal

Chlortetracycline is typically formulated as a single-ingredient medicine, with its activity derived entirely from the Chlortetracycline Hydrochloride component. The drug is made available in several dosage forms for different administration routes, including oral capsules or tablets for systemic effect, as well as topical preparations such as ointments and cutaneous sprays for localized application. The topical preparations are often used in veterinary medicine for managing superficial skin infections, highlighting a key differentiating factor in the product's market positioning. It has an established role in addressing infectious processes caused by susceptible organisms. This confirms that the medicine has a proven ability to target and help control certain infections. The core therapeutic goal remains to stabilize the infection and limit the microbial population, allowing the body's natural defenses to manage the remaining pathogens.

Regulatory References

  1. Tetracyclines: Mechanism of Action

What side effects are possible with Cyclo?

Possible side effects and safety information

The safety profile of Cyclo (Chlortetracycline) is documented by regulatory authorities and includes adverse reactions classified by frequency and affected organ system. The most common adverse reactions relate to the Gastrointestinal system, often presenting as nausea, vomiting, or diarrhea. The official labels also classify effects on the Skin and subcutaneous tissue (e.g., rash, photosensitivity) as generally uncommon.


Serious and Population-Specific Safety Statements

Certain adverse reactions are documented as rare but clinically significant, including Intracranial Hypertension (pseudotumor cerebri), severe Hepatic Dysfunction, and acute Anaphylaxis. Furthermore, the medicine is associated with a risk of Clostridioides difficile-associated diarrhea (CDAD).

Key safety constraints apply to specific populations. Regulatory documents mandate that Chlortetracycline is contraindicated in children under eight years of age and during pregnancy due to the risk of causing permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia during bone and tooth development. Patients with pre-existing renal or hepatic impairment require particular caution due to the risk of drug accumulation and associated toxicity.


Exposure-Related Safety and Restrictions

Safety notes include a recognized risk of phototoxicity, where exposure to sunlight or ultraviolet light during treatment can result in severe exaggerated sunburns. There is also a safety restriction regarding the concurrent use with oral retinoids, which is generally discouraged by regulatory bodies because it may increase the risk of Intracranial Hypertension. The potential for superinfections by non-susceptible organisms, such as Candida, may occur during the course of treatment, reflecting the medicine's broad-spectrum activity.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Cyclobenzaprine (Cyclo) is primarily associated with pronounced effects on the Central Nervous System (CNS) and the Cardiovascular System. Documented manifestations in regulatory labeling include drowsiness, agitation, confusion, tremor, slurred speech, and tachycardia. Gastrointestinal symptoms such as nausea and vomiting may also occur.


Critical Outcomes and Immediate Actions

Severe, life-threatening outcomes are officially documented, including cardiac arrest, severe hypotension, cardiac dysrhythmias, and seizures. The official labeling also notes the potential for Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome in toxicity situations.

Older adults are specified as a population at higher risk for certain severe events, including adverse cardiac effects and increased confusion. Immediate action is mandatory. Individuals must seek emergency medical attention upon known or suspected overexposure. Regulators instruct calling the Poison Help line (1-800-222-1222) or contacting emergency services immediately, especially if the person has collapsed, is experiencing a seizure, or has trouble breathing.


Management and Monitoring

Treatment for overdose is symptomatic and supportive as no specific antidote is known. Due to the risk of critical outcomes, management requires mandatory hospital monitoring, including close cardiac monitoring to detect and manage potential dysrhythmias and continuous observation for signs of CNS or respiratory depression.

Therapeutic Uses of Cyclo

Cyclo is a medication relevant in therapeutic contexts where short-term symptomatic assistance is needed for acute, painful musculoskeletal conditions. It is indicated as an adjunct to rest and physical therapy. The primary therapeutic benefit may include the relief of muscle spasm and its associated symptoms related to physical discomfort, such as pain and tenderness.

It is commonly used across conditions presenting with acute episodes that cause stiffness and aches. The medication is applied in clinical settings that involve acute or disruptive symptom patterns, often used during phases when symptoms become more noticeable due to temporary physiological imbalance. It helps address symptom clusters that may appear suddenly, and is generally considered relevant when supportive symptom management is appropriate.

The support may help ease the overall symptom load associated with the acute event. This symptomatic relief contributes to easing day-to-day comfort and may assist with maintaining functional stability, supporting patients during difficult episodes by easing distress.

Quick Fact: Relief for Musculoskeletal Pain

“It is commonly used across domains where additional symptomatic support is needed, assisting with temporary physical discomfort and stiffness.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Cyclo?

The official eligibility for Cyclo (Chlortetracycline) is defined by regulatory bodies based on specific population categories, physiological states, and pre-existing conditions, strictly as documented in official government labeling.


Contraindicated Populations

Use is contraindicated in individuals with a known hypersensitivity to Chlortetracycline or any other antibiotic in the tetracycline class. The drug is also contraindicated for use by pregnant individuals, particularly during the latter half of pregnancy, due to documented risks of fetal toxic effects.


Age-related eligibility rules

Routine use is not recommended in children under 8 years of age. This restriction is due to the potential for permanent tooth discoloration and inhibition of skeletal development. The medicine is approved for use in adults and children 8 years of age and older.


Condition-specific eligibility rules

Patients with renal impairment (impaired kidney function) are eligible for conditional use. The official labeling mandates a specific reduction in the total dosage. Use is also not recommended for breastfeeding individuals due to the drug's excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cyclo (Chlortetracycline) is defined by official regulatory documentation, outlining specific restrictions and constraints on co-administration with certain substances.

Documented Interaction Patterns

Interaction Type Interacting Agent Official Regulatory Outcome
Formal Contraindication Methoxyflurane Risk of fatal renal toxicity; co-administration is prohibited.
Reduced Exposure Antacids, Iron Supplements, Dairy Products Chelation with multivalent cations reduces drug absorption and systemic concentration.
Pharmacodynamic Potentiation Oral Anticoagulants (e.g., Warfarin) Increased effect of the anticoagulant due to depression of plasma prothrombin activity.
Pharmacodynamic Toxicity Risk Oral Retinoids (e.g., Isotretinoin) Increased risk of Intracranial Hypertension (pseudotumor cerebri).

Administration Constraints and Notes

The interaction with multivalent cations requires a timing constraint; the regulatory guidance states that Chlortetracycline must be administered at least two hours apart from antacids, calcium salts, or iron preparations to mitigate chelation and subsequent loss of systemic exposure. Furthermore, the drug's role as a CYP3A4 inhibitor is officially noted, which may increase the exposure of co-administered medicines that are metabolized by this pathway. An interaction note is also documented for patients with renal impairment, where reduced clearance increases the risk of excessive accumulation and potential toxicity when co-administered with other substances.

Mechanism of Action

DNA Alkylation and Cell Destruction

The medication is administered as an inactive prodrug that requires activation by hepatic (liver) enzymes, specifically the cytochrome P450 system. This essential metabolic step converts the compound into its highly reactive cytotoxic form, phosphoramide mustard. This active metabolite functions as an alkylating agent, chemically modifying the DNA within proliferating cells by creating irreversible cross-links between and within the DNA strands. This damage overwhelms the cell’s repair mechanisms, arresting the cell cycle and inducing apoptosis (programmed cell death), which results in the physiological consequence of limiting cell proliferation in susceptible tissues.

Targeted Immune Cell Suppression

Through the same DNA damage cascade, the drug exerts a specific cytotoxic effect on rapidly proliferating immune cells, notably T-lymphocytes and B-lymphocytes. By reducing the population and activity of these key regulatory cells, the mechanism leads to a systemic reduction of the overall immune system activity.

Dosage and Administration Information

The usage of Cyclobenzaprine (Cyclo) is governed by specific instructions concerning the administration route, duration, and dosing. The route of administration for all dosage forms is oral. The course of treatment is short-term, with a maximum duration of two or three weeks.

Administration and Dosing Regimens

Instruction Standard Regimen
IR Tablet Dosing Standard starting dose is 5 mg taken three times daily (t.i.d.); maximum daily dose is 60 mg.
ER Capsule Dosing Initial dose is 15 mg taken once daily; may be increased to 30 mg once daily.
Timing IR tablets may be taken with or without food. ER capsules should be taken at approximately the same time each day.

Special Administration Conditions

Specific procedural protocols apply to certain patient groups. For older adults (over 65 years), the Immediate-Release (IR) formulation should be initiated at a low dose of 5 mg, with consideration for less frequent administration. The Extended-Release (ER) capsules are generally not recommended in this population.

Regarding preparation, ER capsules must be swallowed whole; however, the capsule contents may be sprinkled onto one tablespoon of applesauce and swallowed immediately without chewing. Tablets and whole capsules must not be crushed or cut. These instructions define the time-limited approach to the use of Cyclobenzaprine.

Recent Clinical Evidence

Research evidence / Overview of studies for Cyclo (Chlortetracycline)


Evidence for Ocular and Surface Bacterial Infections

Research exploring the use of Chlortetracycline for surface infections, particularly in the eyes, has examined findings from Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily focused on populations of adults and children presenting with common bacterial infections like conjunctivitis. Researchers studied outcomes linked to inflammatory or irritative states. The primary goals were to measure endpoints related to symptom outcomes (such as discharge) and to track the elimination of the specific bacterium causing the infection.

Trials report how symptoms evolved in the observed populations over defined time intervals. Systematic reviews that examined topical Chlortetracycline against newer antibiotic options described findings that varied across studies. Research highlights changes measured during the study period, with outcomes reflecting the specific conditions under which they were conducted. Data for certain groups remain insufficient, especially for patients with complex underlying eye conditions. Furthermore, comparative evidence is lacking against an inactive placebo for all indications, as trials often compared against other active drugs.


Research Supporting Veterinary and Regulatory Use

The vast majority of research and regulatory data for Chlortetracycline is derived from veterinary medicine, where it was studied for conditions associated with acute or disruptive episodes, such as bacterial diarrhea in farm animals. The evidence base here is relevant to regulatory contexts in these settings.

Beyond clinical outcomes, a significant area of research was evaluated in animals is the regulatory safety profile for human consumption. Studies explored the drug's journey through the animal body using pharmacokinetic (PK) studies and residue depletion trials. These investigations described patterns related to how the drug is absorbed and eliminated, reporting the tissue residue levels found in various edible tissues that are evaluated against government standards.

Studies on Antimicrobial Resistance and Public Health

Observational studies and surveillance programs track the development and spread of antibiotic-resistant bacteria in various animal and environmental samples. The studies suggest that the widespread use of Chlortetracycline was associated with the emergence of specific resistance patterns in certain common bacterial strains. Research describes the need for ongoing surveillance to monitor these public health concerns.


Areas of Uncertainty and Research Gaps

Evidence is limited in several key areas. The results apply only to the populations studied, meaning the findings from animals cannot be extrapolated to humans, and vice versa. The focus on short-term efficacy for acute events means there is limited information for long-term outcomes regarding the original infection. Finally, the extensive evidence on antimicrobial resistance highlights a critical research gap: understanding how future use can be balanced against the need to preserve antibiotic effectiveness for both human and animal medicine.

Frequently Asked Questions (FAQ)

Common questions about Cyclo (FAQ)

Q: What is the main reason doctors prescribe Cyclo?

Official labeling and regulatory documents indicate that this medication is used for treating a variety of infections caused by susceptible bacteria. This includes specific infections of the eye, skin (like severe acne), respiratory tract, and some sexually transmitted infections, as described in the official product information.


Q: Are there any specific foods or drinks I should avoid while taking Cyclo?

Official documents state that the medication's absorption is impaired by food and certain products, particularly dairy products, as well as antacids, iron, and calcium supplements. Regulatory guidance often describes administration conditions, such as taking the oral form with a full glass of water on an empty stomach (one hour before or two hours after meals), as a way to support proper absorption.


Q: Why is Cyclo sometimes used for different conditions?

The medicine is classified as a broad-spectrum anti-infective agent. This classification means it has the ability to control the growth of a wide variety of different bacterial pathogens, leading to its authorized use in treating various types of infections in susceptible tissues.


Q: Are there different versions or strengths of Cyclo available?

Official regulatory documents confirm that the drug is available in various forms for different routes, including capsules, tablets, ointment, and cutaneous spray. The specific dosage strengths available for each of these forms are detailed in the full prescribing information provided by the regulatory authorities.


Q: Is Cyclo known to interact with herbal supplements?

Official patient safety information consistently states the importance of reporting to a healthcare provider all prescription and nonprescription medicines, vitamins, and supplements being taken. This includes nutritional supplements and herbal products, as interactions with any co-administered substance can occur.


Q: What are the signs of a serious side effect from Cyclo?

Signs of serious side effects that require attention are described in the regulatory safety information. These may include severe headache, dizziness, vision changes, or persistent watery diarrhea, which can be linked to conditions such as increased pressure around the brain or severe bowel infections.


Q: What is the role of Cyclo in treating [Disease Category]?

According to the official prescribing information, the medicine is used for treating specific infections caused by susceptible organisms. These uses include certain infections of the respiratory tract, eye, skin (such as severe acne), and specific sexually transmitted infections.


Q: Are there any special instructions for taking Cyclo related to meals?

The conditions for use described in regulatory documents commonly emphasize that the oral form of the medication is generally to be taken on an empty stomach. Specifically, this is defined as at least one hour before a meal or two hours after a meal, and with plenty of fluid, to minimize stomach irritation and maximize drug absorption.


Q: Is Cyclo available as a generic drug?

The active ingredient in the medicine is Chlortetracycline Hydrochloride. This active ingredient name is the official generic name for the medicine as defined in regulatory databases.


Q: Is Cyclo considered a high-risk medication?

While regulatory documents do not use the term 'high-risk,' they do include multiple serious warnings and contraindications. These warnings specifically relate to use in pregnant individuals, children under 8, and those with reduced kidney or liver function, highlighting significant population-specific risks.


Q: Do clinical trials of Cyclo include diverse patient populations?

Studies summarized in the official research evidence include populations of both adults and children for specific indications. However, the regulatory documents also note that evidence and data for certain specific patient groups remains insufficient.


Q: Does Cyclo need to be refrigerated or stored specially?

Official storage guidance describes the necessary conditions, stating that the medicine should be kept in its container with the cap tightly closed and protected from freezing, excessive heat, and direct light. Refrigeration is not typically specified as a requirement.


Q: Can I take Cyclo if I am also taking over-the-counter pain relievers?

Official information does not typically list a specific interaction between this medicine and common over-the-counter pain relievers such as acetaminophen. However, regulatory guidance consistently emphasizes the importance of reporting to a healthcare provider all over-the-counter products being taken, as interactions can occur.


Q: Does Cyclo interact with caffeine or alcohol?

Official documentation does not list a specific formal interaction or prohibition with caffeine. While it is not a formal contraindication to avoid alcohol, regulatory guidance suggests consulting a healthcare provider about alcohol use during treatment.


Q: Is it normal to feel tired when starting Cyclo?

Tiredness or unusual weakness is not consistently listed as a common or frequent adverse reaction in the official Chlortetracycline product information. Regulatory labels focus on the adverse reactions that have been established through clinical data.


Q: Does taking Cyclo impact driving ability?

There is no blanket prohibition on driving in the official product information. However, the regulatory label does list dizziness and visual changes as rare signs of a serious side effect. Dizziness and visual changes are symptoms that, if they occur, can affect normal functioning.


Q: Do older adults (seniors) need special considerations when taking Cyclo?

While there is no specific age-based restriction for seniors, special caution and dosage adjustment may be necessary. This is especially true for patients who have reduced kidney or liver function, which is a condition often observed in older adults.


Q: Can Cyclo interact with birth control pills?

Regulatory information for the tetracycline class of antibiotics notes that they may potentially reduce the effectiveness of oral contraceptive pills. For this reason, a supplemental or alternative form of contraception may be discussed with a healthcare provider.


Q: Does Cyclo have a 'Black Box Warning' or similar advisory?

Regulatory documents do not contain a specific Boxed Warning, often referred to as a Black Box Warning, for Chlortetracycline. The product labeling includes standard Warnings and Precautions sections to detail potential serious risks.

How should Cyclo be stored and disposed of?

How to Store and Dispose of Chlortetracycline (Cyclo)

Official labeling defines strict conditions for storing and disposing of Chlortetracycline to maintain product integrity and safety.

Storage Requirements

The medicine must be stored out of the reach of children and kept in the container it came in, with the cap tightly closed. Storage conditions must protect the product from freezing, excessive heat, and direct light. For ointments, regulatory guidance requires wiping the tip of the tube with a clean tissue after each use.

Disposal Instructions

Do not keep outdated medicine. Disposal of unused or expired Chlortetracycline must follow official guidance. The preferred method is using a drug take-back program. If no program is available, the medicine must be mixed with an undesirable substance (like dirt or coffee grounds) and sealed in a bag before being placed in the trash. Do not flush the product down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cyclo found in:

A-Z Index: